Illumina, Inc., a biotechnology company based in Delaware, has filed a Schedule 13G with the U.S. Securities and Exchange Commission on August 14, 2024, indicating a significant ownership stake in GRAIL, Inc. following a corporate spin-off. On June 24, 2024, Illumina completed the distribution of approximately 85.5% of GRAIL's common stock to Illumina's shareholders. Post spin-off, Illumina retained direct ownership of 4,502,126 shares, representing 14.5% of GRAIL's outstanding common stock. The filing also notes that Illumina has granted GRAIL a proxy to vote its shares in alignment with the majority of GRAIL's stockholders. The reported ownership percentage is based on 31,049,148 shares of GRAIL's common stock outstanding as of August 11, 2024.

Illumina, Inc., a biotechnology company based in Delaware, has filed a Schedule 13G with the U.S. Securities and Exchange Commission on August 14, 2024, indicating a significant ownership stake in GRAIL, Inc. following a corporate spin-off. On June 24, 2024, Illumina completed the distribution of approximately 85.5% of GRAIL's common stock to Illumina's shareholders. Post spin-off, Illumina retained direct ownership of 4,502,126 shares, representing 14.5% of GRAIL's outstanding common stock. The filing also notes that Illumina has granted GRAIL a proxy to vote its shares in alignment with the majority of GRAIL's stockholders. The reported ownership percentage is based on 31,049,148 shares of GRAIL's common stock outstanding as of August 11, 2024.